Welcome to Peptide Card of AntiTbPdb
| This page displays user query in tabular form. |
GLLKFIKKLL details |
| Primary information | |
|---|---|
| ID | antitb_1863, |
| Name | 27862650 |
| N-Terminal modification | Anoplin |
| C-Terminal Modification | GLLKFIKKLL |
| Chemical Modification | Free |
| Linear/Cyclic | Amidation |
| Length | None |
| Chirality | Linear |
| Nature | 10 |
| Source | L |
| Origin | Amphipathic |
| Species | Synthetic |
| Strain | Anlogue of Anoplin |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis mc2 158 |
| Cell Line | MIC = 15 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 2016 |
| Cytotoxicity | RBC |
| In vivo Model | NA |
| Lethal Dose | Non toxic to erythrocytes |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antifungal (C. parapsilosis) and Antibacterial (Escherichia coli DH5a, Pseudomonas aeruginosa PAO, and Zymomonas mobilis ATCC 10988; Gram-positive bacteria: Bacillus subtilis DELTA) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1866, |
| Name | 27862650 |
| N-Terminal modification | Anoplin |
| C-Terminal Modification | GLLKFIKKLL |
| Chemical Modification | Addition of octanoic acid (C8H16O2) |
| Linear/Cyclic | Amidation |
| Length | None |
| Chirality | Linear |
| Nature | 10 |
| Source | L |
| Origin | Amphipathic |
| Species | Synthetic |
| Strain | Anlogue of Anoplin |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis mc2 161 |
| Cell Line | MIC = 5 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 2016 |
| Cytotoxicity | RBC |
| In vivo Model | NA |
| Lethal Dose | Non toxic to erythrocytes |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antifungal (C. parapsilosis) and Antibacterial (Escherichia coli DH5a, Pseudomonas aeruginosa PAO, and Zymomonas mobilis ATCC 10988; Gram-positive bacteria: Bacillus subtilis DELTA) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1867, |
| Name | 27862650 |
| N-Terminal modification | Anoplin |
| C-Terminal Modification | GLLKFIKKLL |
| Chemical Modification | Addition of decanoic acid (C10H20O2) |
| Linear/Cyclic | Amidation |
| Length | None |
| Chirality | Linear |
| Nature | 10 |
| Source | L |
| Origin | Amphipathic |
| Species | Synthetic |
| Strain | Anlogue of Anoplin |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis mc2 162 |
| Cell Line | MIC = 5 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 2016 |
| Cytotoxicity | RBC |
| In vivo Model | NA |
| Lethal Dose | Non toxic to erythrocytes |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antifungal (C. parapsilosis) and Antibacterial (Escherichia coli DH5a, Pseudomonas aeruginosa PAO, and Zymomonas mobilis ATCC 10988; Gram-positive bacteria: Bacillus subtilis DELTA) |
| Tertiary Structure (Technique) | Not Predicted), |
| Primary information | |
|---|---|
| ID | antitb_1868, |
| Name | 27862650 |
| N-Terminal modification | Anoplin |
| C-Terminal Modification | GLLKFIKKLL |
| Chemical Modification | Addition of dodecanoic acid (C12H24O2) |
| Linear/Cyclic | Amidation |
| Length | None |
| Chirality | Linear |
| Nature | 10 |
| Source | L |
| Origin | Amphipathic |
| Species | Synthetic |
| Strain | Anlogue of Anoplin |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis mc2 163 |
| Cell Line | MIC = 5 μg/mL |
| Inhibition Concentration | In vitro |
| Sequence | 2016 |
| Cytotoxicity | RBC |
| In vivo Model | NA |
| Lethal Dose | Non toxic to erythrocytes |
| Immune Responce | NA |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | NA |
| Other activities | NA |
| PMID | NA |
| Year of Publication | Antifungal (C. parapsilosis) and Antibacterial (Escherichia coli DH5a, Pseudomonas aeruginosa PAO, and Zymomonas mobilis ATCC 10988; Gram-positive bacteria: Bacillus subtilis DELTA) |
| Tertiary Structure (Technique) | Not Predicted), |